StemCell Institute Inc. (TYO:7096)

StemCell Institute Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	565	441	278	212	91
Depreciation & Amortization	128	120	104	96	32
Loss (Gain) From Sale of Investments	-136	-22	-	-	-
Other Operating Activities	-148	-111	-108	11	-118
Change in Accounts Receivable	-252	-447	-546	-314	-
Change in Inventory	-8	-2	-	-8	-15
Change in Accounts Payable	-21	18	-10	72	-36
Change in Other Net Operating Assets	339	337	381	400	284
Operating Cash Flow	467	334	99	469	238
Operating Cash Flow Growth	39.82%	237.37%	-78.89%	97.06%	-
Capital Expenditures	-478	-183	-56	-181	-402
Cash Acquisitions	-34	-	-	-	-
Sale (Purchase) of Intangibles	-96	-18	-3	-23	-1
Investment in Securities	357	-627	-142	750	-105
Other Investing Activities	-9	17	-84	-142	-12
Investing Cash Flow	-259	-811	-285	404	-520
Long-Term Debt Issued	510	-	-	-	-
Long-Term Debt Repaid	-11	-	-	-	-
Net Debt Issued (Repaid)	499	-	-	-	-
Issuance of Common Stock	-	-	-	644	-
Repurchase of Common Stock	-94	-	-	-	-
Dividends Paid	-255	-	-	-	-
Other Financing Activities	-4	-1	-	-	-
Financing Cash Flow	146	-1	-	644	-
Miscellaneous Cash Flow Adjustments	1	-	-	-	1
Net Cash Flow	355	-478	-186	1,517	-281
Free Cash Flow	-11	151	43	288	-164
Free Cash Flow Growth	-	251.16%	-85.07%	-	-
Free Cash Flow Margin	-0.41%	6.09%	2.06%	16.17%	-11.64%
Free Cash Flow Per Share	-1.07	14.74	4.20	56.87	-33.70
Cash Interest Paid	1	-	-	-	-
Cash Income Tax Paid	144	110	109	-8	124
Levered Free Cash Flow	7.25	56.75	56.25	236.88	-112.63
Unlevered Free Cash Flow	7.88	56.75	56.25	236.88	-112.63
Change in Working Capital	58	-94	-175	150	233

Source: S&P Global Market Intelligence. Standard template. Financial Sources.